Royal Bank of Canada
APRE icon

Royal Bank of Canada’s Aprea Therapeutics APRE Stock Holding History

Royal Bank of Canada’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,694
Closed -$23K – 6817
2024
Q2 		$23K Buy
5,694
+3,124
+122% +$16.1K ﹤0.01% 6006
2024
Q1 		$17K Sell
2,570
-41,455
-94% -$258K ﹤0.01% 5979
2023
Q4 		$207K Buy
44,025
+43,708
+13,788% +$179K ﹤0.01% 5075
2023
Q3 		$1K Buy
317
+194
+158% +$707 ﹤0.01% 6855
2023
Q2 		$0 Buy
123
+100
+435% +$373 ﹤0.01% 7216
2023
Q1 		$0 Buy
+23
New +$170 ﹤0.01% 7043
2022
Q2 		– Sell
-585
Closed -$22K – 7340
2022
Q1 		$22K Hold
585
– – ﹤0.01% 6545
2021
Q4 		$34K Sell
585
-445
-43% -$39.3K ﹤0.01% 6571
2021
Q3 		$105K Sell
1,030
-28
-3% -$2.54K ﹤0.01% 5661
2021
Q2 		$104K Buy
1,058
+299
+39% +$27.6K ﹤0.01% 5578
2021
Q1 		$76K Buy
759
+329
+77% +$38.4K ﹤0.01% 5632
2020
Q4 		$42K Buy
430
+375
+682% +$178K ﹤0.01% 5736
2020
Q3 		$27K Buy
55
+40
+267% +$22.4K ﹤0.01% 5573
2020
Q2 		$12K Buy
15
+14
+1,400% +$9.19K ﹤0.01% 5762
2020
Q1 		$1K Sell
1
-6
-86% -$4.4K ﹤0.01% 6394
2019
Q4 		$7K Buy
+7
New +$3.85K ﹤0.01% 6242

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's APRE Position: Q3 2024 in Review

Royal Bank of Canada sold out of Aprea Therapeutics (APRE) in Q3 2024, closing a stake of 5,694 shares — an estimated $23K sold.

Royal Bank of Canada first reported a position in APRE in Q4 2019 and held it in 16 quarters. The position peaked at $207K in Q4 2023. 22 funds tracked by Wall St. Rank hold APRE as of Q3 2024.

  • Royal Bank of Canada reported no remaining Aprea Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 5,694 Aprea Therapeutics shares in Q3 2024, an estimated $23K.
  • Royal Bank of Canada first reported a position in Aprea Therapeutics in Q4 2019 and held it in 16 quarters.
  • Royal Bank of Canada's Aprea Therapeutics position peaked at $207K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.